FibroBiologics regains full compliance with Nasdaq listing requirements; monitoring periods imposed

FibroBiologics, Inc.

Nasdaq confirmed compliance with $2.5M stockholders' equity rule (Mar 9) and $1.00 bid price rule (Apr 17).
One-year Mandatory Panel Monitor for both equity and bid price; failure during monitor triggers delist determination without cure period.
Company remains listed on Nasdaq Capital Market under symbol FBLG; all prior listing matters closed.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.